澳洲微盘药房基础设施公司PharmX(ASX:PHX)Q1 FY27运营更新：收入同比+9%、Marketplace季GTV环比+150%，但无正式业绩指引、股价贴近52周低位

Wall Street ends marginally lower after softness in memory stocks, bank earnings
Introduction & Market Context
Pharmx Technologies Limited (ASX:PHX) presented its first-quarter fiscal 2027 results on October 14, 2026, highlighting accelerating marketplace growth and the successful launch of its upstream Relay EDI platform. The pharmacy infrastructure company reported 9% revenue growth year-over-year while continuing its strategic shift from fixed account fees to volume-based revenue models.
The company’s shares traded at $0.083 following the presentation, down 1.19% and near the bottom of their 52-week range of $0.08 to $0.20, suggesting investor caution persists despite operational progress.
Quarterly Performance Highlights
PharmX reported solid growth across its core metrics in the first quarter of fiscal 2027. Revenue increased 9% compared to the prior corresponding period, with the company’s recurring revenue composition shifting notably toward volume-based fees. The proportion of recurring revenue generated from volume-based sources rose to 24% year-to-date, up from 20% in the prior fiscal year.
As shown in the following breakdown of Q1 FY27 performance across key business segments:
The company’s platform metrics demonstrated strong momentum. Gateway order transmission increased 12% year-over-year, while total pharmacy-to-supplier account connections grew 3% year-to-date and active accounts expanded 4%. New supplier signings during the quarter included Homart NZ, Pacific Optics, Coolkidz, Equipmed, and X Zone, with Paragon Exclusive Promotions scheduled to go live in November.
PharmX operates at the center of the Australia and New Zealand pharmacy supply chain, connecting 99% of pharmacies across the region. The company’s network processes approximately A$26 billion in annual volume flow across more than 500 million document lines per year, handling 120,000 active SKUs.
The following overview illustrates the company’s integrated platform approach and scale of operations:
Marketplace Acceleration
The most dramatic growth came from PharmX’s Marketplace platform, which reached A$6.9 million in gross transaction value (GTV) in September 2026. This represented approximately 150% growth compared to the prior quarter and 45% growth versus the prior month, putting the platform on an annualized run-rate of roughly A$83 million.
Management outlined a clear pathway toward a A$100 million annualized run-rate target by March 2027, supported by improving user engagement metrics. The platform now serves approximately 2,000 registered entities processing around 10,000 orders.
The following chart demonstrates the marketplace’s GTV trajectory and growth targets:
User engagement metrics showed substantial improvement. Among the target cohort, monthly purchase frequency increased 39% in Q1 FY27 versus Q4 FY26 to 24.6 transactions, while total marketplace monthly purchase frequency surged 83% to 13.9. Monthly spend per pharmacy in the target cohort reached approximately A$102,000 in September, up 58% quarter-over-quarter, while total marketplace monthly spend per pharmacy climbed 122% to around A$50,000.
Cart abandonment rates fell to below 1%, down from 30-40% at launch, while the time from customer acquisition to first trade dropped to 1.4 days in September from approximately 60 days initially.
PharmX identified a serviceable addressable market of approximately A$12 billion for its Marketplace platform. The company outlined a pathway to A$1 billion in annual GTV supported by approximately 500 primary customers spending around 40% of their current procurement through the platform, plus roughly 1,500 non-primary customers at about 15% of current spend.
The company’s marketplace strategy and market opportunity are detailed in the following breakdown:
Product innovation priorities for fiscal 2027 include launching Smart Cart for order automation, developing mobile and at-shelf ordering capabilities, and implementing group controls for head office and representative functions.
EDI Platform Expansion
PharmX achieved a significant milestone with the September 2026 operational launch of its Relay EDI solution at Sigma Healthcare’s new South Auckland distribution center. This marked the first agreed work item under the companies’ multi-year strategic alliance and represented PharmX’s expansion upstream in the pharmacy supply chain.
The Relay platform extends PharmX’s EDI capabilities from distribution centers to manufacturers and suppliers, handling purchase orders, advanced shipping notices, and invoices. The company has integrated 12 EDI Relay customers to date, with 10 implementations in process, 40 in the pipeline over fiscal 2027, and 140 target suppliers identified.
The following diagram illustrates how Relay and Gateway create an integrated platform across the pharmacy supply chain:
The downstream Gateway platform continued to show solid growth, with orders up 12% year-over-year and GTV increasing 15%. The company signed three new Gateway suppliers during the quarter while total pharmacy-to-supplier accounts grew 3% year-to-date.
Gateway and Relay performance metrics for Q1 FY27 are shown in the following summary:
PharmX emphasized its unique position in being able to move up the value chain with Relay, noting that upstream competitors cannot easily move downstream due to the complexity of pharmacy point-of-sale integrations. The company highlighted its AI-native approach, which has reduced supplier onboarding time from weeks to hours by accepting any data format and converting it to queryable structured data.
The strategic advantages and expanded market opportunity across the EDI platforms are illustrated below:
The combined serviceable GTV opportunity across PharmX’s EDI platforms spans more than A$20 billion in existing core services from distribution centers to stores, approximately A$9 billion in upstream services from suppliers to distribution centers, and roughly A$14 billion in full vertical services to international markets.
Strategic Partnerships
PharmX’s strategic alliance with Sigma Healthcare (ASX:SIG) represents a cornerstone of the company’s growth strategy. Under the multi-year partnership, Sigma holds a 10% equity position in PharmX and has appointed a board representative.
The alliance aims to generate approximately A$9 million in new revenues under Part A, which focuses on securing and expanding core business. Part B of the agreement includes a pathway for Sigma to increase its ownership to 19.9%, with an agreed percentage of Part B revenue used to acquire additional equity once per year at market price. Management estimates A$30-50 million in new revenues would be required for the additional 9.9% stake, with no increase expected in fiscal 2027.
The structure and objectives of the Sigma alliance are detailed in the following breakdown:
PharmX also announced a commercial strategic collaboration with IQVIA, a leading global provider of advanced analytics, and Hypercube Scientific, a data science and technology company. The partnership aims to deliver differentiated solutions to suppliers and retailers across the Australian and New Zealand pharmacy industries, primarily focused on supply chain optimization and automation.
Detailed Financial Analysis
Fiscal 2026 results, which concluded in June 2026, provided context for the company’s Q1 FY27 performance. Total revenue reached A$7.74 million, up 3% compared to fiscal 2025. Gateway revenue increased 8% excluding market structural changes, while Marketplace revenue surged 73% and New Zealand revenue jumped 67%.
The company’s FY26 financial performance is summarized in the following metrics:
Gross margin improved to 84%, a 2 percentage point increase over fiscal 2025, reflecting the company’s shift toward higher-margin volume-based revenue streams. EBITDA remained positive at A$1.1 million, though down A$0.5 million compared to fiscal 2025 as the company invested in platform development and market expansion.
PharmX maintained a cash position of A$2.6 million as of June 2026 with positive operating cash flows. The company reported that more than 88% of fiscal 2027 revenue is already recurring or contracted, providing visibility into near-term financial performance.
Platform insights for fiscal 2026 revealed strong growth across multiple product categories beyond core pharmacy items. GLP-1 medications showed particularly robust expansion, rising from 7.5% to 11.8% of trade and accounting for 50.8% of overall growth. The category’s revenue increased 75% to A$2.5 billion, with Mounjaro’s share of the GLP-1 category rising from 31% to 53%.
Product category performance across the platform is illustrated below:
Outside GLP-1, the platform demonstrated 5.8% growth, with specialty products across five therapy areas adding A$470 million and representing 45% of growth outside GLP-1. Personal care grew 16.5% from A$1.6 billion to A$1.9 billion, while beauty emerged as the fastest-growing large category with 22.9% expansion from A$292 million to A$359 million. Medicinal cannabis showed 33.4% growth, reaching A$65 million in trade.
Platform Capabilities and Product Suite
PharmX emphasized its integrated single-platform approach, which connects manufacturers, distributors, suppliers, and pharmacies across Australia and New Zealand through shared services and specialized capabilities.
The comprehensive product suite spanning Relay, Gateway, and Marketplace is detailed in the following overview:
All three platforms share core infrastructure including single sign-on, unified integration, supplier and demand analytics, self-service onboarding, and secure high-availability infrastructure. However, each platform offers specialized capabilities tailored to specific supply chain segments.
Gateway provides enterprise ERP integration, robo-dispense connectivity, CSO wholesaler integration, and CRM capabilities. The platform synchronizes invoices to pharmacy point-of-sale systems including FRED, Minfos, and Z, while supporting e-invoicing compliance and three-way matching.
Marketplace adds unique features including smart price visibility showing last price paid, a promotions hub with exclusive deals, and trade marketing capabilities. Both Gateway and Marketplace support real-time order processing, multi-supplier cart functionality, bulk orders, templates, and planogram ordering.
The matrix of shared services and platform-specific capabilities is shown below:
Forward-Looking Statements
Management outlined an ambitious growth agenda for fiscal 2027 and beyond. The company is targeting double-digit revenue growth and cash flow breakeven for the current fiscal year, with margin expansion planned for fiscal 2028 and beyond.
Key strategic priorities include expanding supplier participation across all platforms, adding more wholesalers to the marketplace, rolling out Relay EDI in New Zealand and commencing Australian deployment, and building new revenue streams from data and analytics, advertising, and payments.
For the Marketplace platform specifically, fiscal 2027 product innovation will focus on launching Smart Cart for order automation, developing mobile and at-shelf ordering capabilities, and implementing group controls for head office and representative functions. The company aims to drive growth through margin expansion with more manufacturers and distributors, increasing store participation and monthly spend across all cohorts, and developing marketing and advertising revenue within the platform.
The Relay EDI platform’s fiscal 2027 priorities include supplier scaling, supporting the New Zealand rollout with Sigma’s distribution center, and commencing the Australian market rollout. For Gateway, the company plans to continue supplier scaling, launch Gateway 5 with AI innovations, migrate suppliers to a single platform with higher-value services and new revenue models, and pursue horizontal expansion including hospital ordering.
The company’s "Network Plus" strategy aims to transform PharmX into the primary pharmacy ordering platform, deliver a full vertical EDI solution for pharmacy, and create the most impactful data solution in the market. This evolution is supported by partnerships with Sigma and IQVIA serving as accelerators, along with AI deployment to maintain a low-cost base while advancing platform capabilities.
Management emphasized that the shift from today’s model—where 80% of annual recurring revenue comes from flat account fees averaging A$15 per month per pharmacy-supplier connection—to the Network Plus model will generate revenues based on volume across Relay and Marketplace, with analytics revenue from data-as-a-service subscriptions.
While the company outlined a pathway to A$1 billion in annual marketplace GTV over approximately three years, management did not provide formal revenue guidance tied to that target. The presentation noted that current reported metrics trajectory supports the emerging pathway to this milestone, assuming approximately 500 primary customers contribute around 40% of their current spend and roughly 1,500 non-primary customers contribute about 15% of their current spend.
Full presentation:
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.